Elena Faleschini

Elena Faleschini

Auto-generated profile, based on publicly available information

Elena Faleschini

Institute for Maternal and Child Health - IRCCS “Burlo Garofolo”, Trieste, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2022 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
MPMartina Peinkhofer
Martina Peinkhofer
BBBenedetta Bossini
Benedetta Bossini
APArturo Penco
Arturo Penco
MGManuela Giangreco
Manuela Giangreco
MPMaria Chiara Pellegrin
Maria Chiara Pellegrin
GTGianluca Tornese
Gianluca Tornese
Background: While several studies have been published so far on the effect of COVID-19 pandemic on health care for non-COVID-19 diseases, to date no study evaluated the impact of the COVID-19 pandemic on the entire field of pediatric endocrinology. This study aimed to evaluate differences in pediatric endocrine stimulation tests after the advent of COVID-19 pandemics. Methods: Retrospective study with data collection for pediatric endocrine stimulation tests performed in 2019 and 2020 in a tertiary center. Results: Overall, 251 tests were performed on 190 patients in 2020, compared to 278 tests on 206 patients in 2019 (− 10% tests; − 8% children evaluated). A significant reduction was found in tests to diagnose growth hormone deficiency (GHD) (− 35%), while LHRH tests increased (+ 22%). A reduction of 30% in GHD diagnosis was observed. Central precocious puberty (CPP) diagnosis increased by 38% compared to 2019, mainly in females. Conclusion: This study found a significant reduction of tests investigating GHD during COVID-19 pandemics. It also showed a clinically meaningful increase in cases of CPP in girls. These results suggest the need for families and pediatricians to monitor children’s growth during isolation and enlighten new perspectives towards conditions associated with lockdown restrictions as increased screen time, social isolation, and children’s anxiety as possible triggers of CPP.

1 May 2006 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
FMFederico Marchetti
Federico Marchetti
TGTania Gerarduzzi
Tania Gerarduzzi
FLFilippo Longo
Filippo Longo
EFElena Faleschini
Elena Faleschini
AValessandro ventura
alessandro ventura
GTGiorgio Tonini
Giorgio Tonini

30 April 2025 in Annals of Pediatric Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
CRChiara Rodaro
Chiara Rodaro
GTGianluca Tamaro
Gianluca Tamaro
EFElena Faleschini
Elena Faleschini
GTGianluca Tornese
Gianluca Tornese
Long-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric GH deficiency, offering an alternative to daily recombinant human GH (rhGH) therapy. Traditional rhGH treatments, although effective, require daily injections, often leading to poor adherence due to the frequency of dosing, injection pain, and difficulties with storage and travel. In contrast, LAGHs, such as somatrogon, somapacitan, and lonapegsomatropin, are designed for once-weekly administration, improving patient compliance and quality of life. LAGHs have demonstrated non-inferiority to daily rhGHs in phase 3 clinical trials, showing similar efficacy in terms of growth velocity and safety profiles. Despite these advantages, concerns remain regarding the altered pharmacodynamics of LAGHs such as the lack of pulsatile secretion and potential for antibody formation. Although the overall safety of LAGHs has been confirmed, side effects, such as lipoatrophy at the injection site, may occur, especially with PEGylated formulations. Guidelines for prescribing LAGHs are currently evolving. LAGHs are not yet approved for other conditions traditionally treated with rhGHs, such as Turner or Noonan syndrome. Pediatric endocrinologists should carefully consider which patient groups would benefit most from this therapy, particularly individuals at risk of poor adherence to daily injections such as patients undergoing multidrug therapy, patients with needle phobia or behavioral disorders, very young children, adolescents, patients with separated parents, families that travel frequently, or children involved in activities such as scouting. LAGHs present an opportunity to enhance therapeutic outcomes and adherence, but careful patient selection remains critical to maximize their potential benefits.

1 December 2019 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
MPMaria Chiara Pellegrin
Maria Chiara Pellegrin
DMDaria Michelon
Daria Michelon
EFElena Faleschini
Elena Faleschini
CGClaudio Germani
Claudio Germani
EBEgidio Barbi
Egidio Barbi
GTGianluca Tornese
Gianluca Tornese
To evaluate glucose metabolism and insulin sensitivity in children with idiopathic growth hormone (GH) deficiency, treated with recombinant human GH (rhGH), and to identify possible risk factors for the development of glucose abnormalities in this population. We retrospectively collected data from 101 patients (60 males, median age 10.4 years, 77 prepubertal), with confirmed GH deficiency, enrolled before starting rhGH and followed up during the first three years of treatment. Glucose metabolism was evaluated annually by oral glucose tolerance test (OGTT) and glycated hemoglobin A1c (HbA1c). OGTT was used to calculate insulin sensitivity (HOMA-S) and insulin resistance (HOMA-IR), defined as HOMA-IR >3. RhGH was effective in improving growth and dosages significantly reduced after the first year of therapy. No patient developed diabetes mellitus. After one year of therapy, a significant increase in HbA1c (p=0.0042) and insulin levels (fasting p<0.0001, 60 min p=0.0018, 120 min p=0.0003) was observed, with a higher prevalence of IR (p<0.05). These indices did not alter further during the follow-up and were not related to GH dose or to family history of diabetes. A significant correlation was found only for IR indices and pubertal status, weight and age (p<0.05). In this retrospective study on a large GH deficient pediatric population, conventional use of replacement therapy resulted in an increase in HbA1c and IR after one year of therapy, regardless of rhGH dosage. These alterations did not worsen significantly in the following two years and were not associated with overt diabetes.

11 March 2021 in Acta Paediatrica
Verified
Journal Article
Open access
PDF file
MCMarta Cognigni
Marta Cognigni
MDMartina D'AGostin
Martina D'AGostin
ISIngrid Schiulaz
Ingrid Schiulaz
MGManuela Giangreco
Manuela Giangreco
CCClaudia Carletti
Claudia Carletti
GTGianluca Tornese
Gianluca Tornese
Click on the article title to read more.

22 December 2023 in Medicina
Verified
Journal Article
Open access
PDF file
MPMaria Chiara Pellegrin
Maria Chiara Pellegrin
CMChiara Marzin
Chiara Marzin
Lorenzo MonastaLorenzo Monasta
Lorenzo Monasta
GTGianluca Tamaro
Gianluca Tamaro
VVViviana Vidonis
Viviana Vidonis
GTGianluca Tornese
Gianluca Tornese
Background and Objectives: The gonadotropin-releasing hormone (GnRH) stimulation test is the gold standard method for diagnosing central precocious puberty (CPP), although it requires multiple blood samplings over 120 min. This study aimed to evaluate if a shorter test may have an equivalent diagnostic accuracy. Materials and Methods: We retrospectively reviewed the GnRH tests of 188 consecutive pediatric patients (169 females) referred for signs of early pubertal development. The diagnostic accuracy of the hormonal levels was evaluated at different time points (15, 0, 60, 90, and 120 min after the GnRH stimulus). Results: A diagnosis of CPP was made in 130 cases (69%), with 111 (85%) being female. Sensitivity and specificity ratings higher than 99% for the diagnosis of CPP were achieved for LH levels ≥4.7 mU/mL at 30 and 60 min after the stimulus (area under the ROC curve (AUC) = 1), with no further increase in the diagnostic accuracy in the remaining time points. No sex differences in diagnostic accuracy were found. The LH/FSH ratio at 30 min showed a sensitivity of 94.9%, with an AUC of 0.997 and a value ≥0.76. Conclusions: A short-duration GnRH test of 60 min provided optimal results for the diagnosis of CPP. Extending the test for an extra hour is therefore unnecessary and inadvisable.